Chlorpromazine equivalent doses for the newer atypical antipsychotics

Journal of Clinical Psychiatry

Volumn 64, Issue 6, 2003, Pages 663-667

  Woods, Scott W ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; DOSE CALCULATION; DOSE RESPONSE; DRUG RESEARCH; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY;

EID: 0038266756     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0607     Document Type: Article

References (40)

1. Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974;11:65-69
2. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59:69-75
3. McEvoy JP, Scheifler PL, Frances A, eds. Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry 1999;60 (suppl 11):1-80
4. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(suppl 4):1-63
5. Remington G, Kapur S, Zipursky R. APA practice guideline for schizophrenia: risperidone equivalents [letter with reply]. Am J Psychiatry 1998;155:1301-1302
6. Remington G, Shammi CM, Sethna R, et al. Antipsychotic dosing patterns for schizophrenia in three treatment settings. Psychiatr Serv 2001;52:96-98
7. Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 1997;11:65-71
8. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68
9. Mattes JA. Risperidone: how good is the evidence for efficacy? Schizophr Bull 1997;23:155-161
10. de Oliveira IR, Miranda-Scippa AM, de Sena EP, et al. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. J Clin Pharm Ther 1996;21:349-358
11. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
12. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics, pt 1: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73-85
13. Bech P, Peuskens JCJR, Marder SR, et al. Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics. Eur Psychiatry 1998;13:310-314
14. Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2000. Oxford, England: Update Software; 2000
15. Gilbody SM, Bagnall AM, Duggan L, et al. Risperidone vs other atypical antipsychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 3, 2000. Oxford, England: Update Software; 2000
16. Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2000. Oxford, England: Update Software; 2000
17. Duggan L, Fenton M, Dardennes RM, et al. Olanzapine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2000. Oxford, England: Update Software; 2000
18. Kennedy E, Song F, Hunter R, et al. Risperidone versus typical anti-psychotic medication for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 3, 2000. Oxford, England: Update Software; 2000
19. Bagnall A-M, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness (Cochrane Review). In: The Cochrane Library, Issue 1, 2001. Oxford, England: Update Software; 2001
20. Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford, England: Update Software; 2002
21. Thornley B, Adams CE, Awad G. Chlorpromazine versus placebo for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford, England: Update Software; 2002
22. Zimbroff DL, Kane JM, Tamminga CA, et al, and the Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-791
23. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40. Correction 1993;13:149
24. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
25. Potkin SG. Efficacy and safety of once-daily dosing with risperidone in patients with schizophrenia. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 21, 1997; San Diego, Calif. Abstract NR590:227
26. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167
27. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial [see comments]. Neuropsychopharmacology 1996;14:111-123
28. Fabre LF Jr, Arvanitis L, Pultz J, et al. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995;17:366-378
29. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-246
30. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998;140:173-184
31. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizo-affective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505
32. FDA/CDER Freedom of Information. Approval Package, Geodon (ziprasidone HCl) capsules. Food and Drug Administration Web site. Available at: http://www.fdagov/cder/foi/nda/2001/20-825_Geodan.htm
33. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
34. FDA/CDER Freedom of Information. Approval Package, Abilify (aripiprazole) tablets. Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/foi/nda/2002/21-436_Abilify_medr_P3.pdf
35. Vichaiya V. Clinical trial of haloperidol in schizophrenia. J Psychiatr Assoc Thai 1971;16:31-43
36. Garry JW, Leonard TJ. Haloperidol: a controlled trial in chronic schizophrenia. J Ment Sci 1962;108:105-107
37. Prien R, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia: report of National Institute of Mental Health-Psychopharmacology Research Branch Collaborative Study Group. Arch Gen Psychiatry 1968;18:482-495
38. Clark ML, Ramsey HR, Ragland RE, et al. Chlorpromazine in chronic schizophrenia: behavioral dose-response relationships. Psychopharmacologia 1970;18:260-270
39. Grygier P, Waters MA. Chlorpromazine used with an intensive occupational therapy program. AMA Arch Neurol Psychiatry 1958;79:697-705
40. Cooper SJ, Tweed J, Raniwalla J, et al. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia. Acta Psychiatr Scand 2000;101:218-225